GEMINI THERAPEUTICS
Gemini Therapeutics is a precision medicine company focused on genetically defined dry age-related macular degeneration (AMD) and associated rare genetic diseases. Their therapeutic candidates are matched to molecular abnormalities found in patients with high clinical needs and our broad multimodal pipeline includes monoclonal antibodies, recombinant proteins, and gene therapies. Launched with funding from leading life science investors and powered by academic partnerships around the world, they are developing a series of potentially first-in-class therapeutics.
GEMINI THERAPEUTICS
Industry:
Biopharma Biotechnology Health Diagnostics
Founded:
2015-01-01
Address:
Cambridge, Massachusetts, United States
Country:
United States
Website Url:
http://www.geminitherapeutics.com
Total Employee:
11+
Status:
Active
Total Funding:
139.5 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Font API Google Analytics LetsEncrypt Apple Mobile Web Clips Icon Google Tag Manager WordPress
Similar Organizations
Edgewise Therapeutics
Edgewise Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization.
Valkyrie GRP
Valkyrie GRP is a growth-oriented investment firm that focuses on team development, early distribution, and solid, value-added partnerships.
Current Advisors List
Board_member
Board_member
Board_member
Board_member
Current Employees Featured
Jason Meyenburg Chief Executive Officer @ Gemini Therapeutics
Chief Executive Officer
2019-09-01
Andy Herbert Scientific Co-Founder & Scientific Advisor @ Gemini Therapeutics
Scientific Co-Founder & Scientific Advisor
2016-02-01
Marc Uknis Chief Medical Officer @ Gemini Therapeutics
Chief Medical Officer
2020-01-01
James McLaughlin President and CEO @ Gemini Therapeutics
President and CEO
2016-04-01
Founder
Stock Details
Investors List
Atlas Venture
Atlas Venture investment in Post-IPO Equity - Gemini Therapeutics
Foresite Capital
Foresite Capital investment in Post-IPO Equity - Gemini Therapeutics
Dafna Capital Management
Dafna Capital Management investment in Post-IPO Equity - Gemini Therapeutics
Suvretta Capital Management
Suvretta Capital Management investment in Post-IPO Equity - Gemini Therapeutics
Lightstone Ventures
Lightstone Ventures investment in Post-IPO Equity - Gemini Therapeutics
Acorn Bioventures
Acorn Bioventures investment in Post-IPO Equity - Gemini Therapeutics
Alyeska Investment Group
Alyeska Investment Group investment in Post-IPO Equity - Gemini Therapeutics
Fidelity Management and Research Company
Fidelity Management and Research Company investment in Post-IPO Equity - Gemini Therapeutics
Wellington Management
Wellington Management investment in Post-IPO Equity - Gemini Therapeutics
Boxer Capital
Boxer Capital investment in Post-IPO Equity - Gemini Therapeutics
Key Employee Changes
| Date | New article |
|---|---|
| 2020-05-07 | Gemini Therapeutics Names Ex-Achillion Exec Marc Uknis Chief Medical Officer |
Official Site Inspections
http://www.geminitherapeutics.com Semrush global rank: 4.15 M Semrush visits lastest month: 2.88 K
- Host name: 104.21.30.30
- IP address: 104.21.30.30
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "Gemini Therapeutics"
We See Disease Differently - Gemini Therapeutics
Gemini Therapeutics is a precision medicine company focused on the development of new therapies through a deeper understanding of disease. We are sharply focused on dry AMD …See details»
About - Gemini Therapeutics
Gemini Therapeutics is a precision medicine company focused on the development of new therapies for dry AMD. We See Disease Differently. We are using our understanding of …See details»
Gemini Therapeutics - Crunchbase Company Profile
Gemini Therapeutics is a precision medicine company focused on genetically defined dry age-related macular degeneration (AMD) and associated rare …See details»
Management Team - Gemini Therapeutics
Our management team has decades of combined pharmaceutical and biotech industry experience. Their wide-ranging expertise in drug research, development, collaborative …See details»
Gemini Therapeutics and Disc Medicine Announce Merger …
Aug 10, 2022 Gemini Therapeutics, Inc. Brian Piekos Gemini Therapeutics, Inc. (617) 401-4400 IR@geminitherapeutics.com Disc Medicine, Inc. Peg Rusconi (Media) Verge Scientific …See details»
Gemini Therapeutics - Org Chart, Teams, Culture
Gemini Therapeutics is a precision medicine company focused on the development of new therapies through a deeper understanding of disease. Industries. Biotechnology. Headquarters. Cambridge, United States. Stage. …See details»
Gemini Therapeutics (USA) Funding: $139.5M - Medical Startups
Mar 11, 2025 Gemini Therapeutics is a precision medicine company focused on genetically-defined dry age-related macular degeneration (AMD) and associated rare genetic …See details»
Gemini Therapeutics, Inc. - Drug pipelines, Patents, Clinical
Mar 8, 2025 Gemini Therapeutics is a company specializing in precision medicine, with a primary focus on genetically determined dry age-related macular degeneration (AMD) and …See details»
Gemini Therapeutics 2025 Company Profile: Valuation, Investors ...
Gemini Therapeutics General Information Description. Disc Medicine Inc is a clinical-stage biopharmaceutical company that is dedicated to transforming the lives of patients with …See details»
Gemini Therapeutics | Company | Mindmaps
Company → «Gemini Therapeutics» Suggest organization ... Suggest organization Claim Ownership Gemini Therapeutics Company. Gemini Therapeutics focuses on genetically-defined dry age-related macular degeneration (AMD) and associated rare genetic diseases. Investors. 4DX Ventures Creative Ventures ...See details»
Gemini Therapeutics - Investor Relations
Gemini is a clinical-stage precision medicine company developing novel therapeutic compounds to treat genetically defined AMD. Its lead candidate, GEM103, is a recombinant form of the …See details»
Gemini Therapeutics - Governance - Board of Directors
Jason Meyenburg is Chief Executive Officer at Gemini Therapeutics. He has more than 20 years of experience in developing and commercializing therapies for patients with serious conditions. …See details»
Gemini Therapeutics Sub - Craft
Gemini Therapeutics Sub is a precision medicine company focused on genetically-defined dry age-related macular degeneration and associated rare genetic diseases. Its therapeutic …See details»
Gemini Therapeutics Announces Corporate Restructuring to …
Oct 5, 2021 Therefore, we are shifting Gemini’s focus from a research and development organization to exclusively become a development-stage company. Gemini will concentrate its …See details»
Gemini Therapeutics Announces Leadership Appointment
Jason Meyenburg Joins Gemini Therapeutics as CEO. Cambridge, Mass., September 13, 2019 – Gemini Therapeutics, a precision medicine company developing innovative treatments for age …See details»
Gemini Therapeutics - Contacts, Employees, Board Members
Organization. Gemini Therapeutics . Connect to CRM . Save . Summary. Financials. People. Technology. Signals & News. ... About. Gemini Therapeutics has 4 current employee profiles, including Chief Executive Officer Jason Meyenburg. Gemini Therapeutics has 4 board members and advisors, including Jason Rhodes. Contacts. Edit Contacts Section. Job ...See details»
Gemini Therapeutics and Disc Medicine Announce Merger …
Aug 10, 2022 About the Proposed Transaction, Management and Organization. ... Gemini Therapeutics, Inc. Brian Piekos Gemini Therapeutics, Inc. (617) 401-4400 …See details»
Gemini axes CSO and 20% of staff to focus on late-phase plans
Oct 5, 2021 Gemini Therapeutics is betting it all on its clinical-phase eye disease prospect. Having built up early-stage activities in gene therapy and other areas, Gemini is now sweeping …See details»
Gemini Therapeutics, Inc. (GMTX): history, ownership, mission, …
[relinking] Home History Owners Mission How It Works How It Makes Money A Brief History of Gemini Therapeutics, Inc. (GMTX) Foundation and Formation Gemini Therapeutics, Inc. was founded in 2015, focusing on developing novel treatments for genetically defined diseases of the eye. The company's primary aim is to address the needs of patients suffering from conditions …See details»
Board of Directors | Gemini Therapeutics
The board members of Gemini Therapeutics have extensive experience in the pharmaceutical industry. Their strategic insights help us achieve our goal of developing and delivering first-in …See details»